ArticleInternational journal of trichology
Comment on Current Investigations into the Postfinasteride Syndrome.
Article in International journal of trichology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few dermatologic problems carry as much emotional overtones as the complaint of hair loss, while the best way to alleviate the emotional distress related to the hair loss is to effectively treat it. With the advent of effective pharmacologic agents, the options for managing male pattern hair loss (MPHL) and alopecia-related distress have expanded. Oral finasteride represents a major breakthrough, based on an understanding of the underlying pathophysiology, and observations on the phenotype of the respective genetic defect of type 2 5-alpha reductase. Clinical studies have demonstrated both a high efficacy of treatment and a favorable safety profile establishing the drug as first-line treatment. And yet, after 15 years of successful prescription, the postfinasteride syndrome has emerged. By definition, the condition is characterized by sexual dysfunction, somatic symptoms, and psychological disorders that persist after cessation of treatment. As yet, the condition is not recognized by the medical community. In fact, the concept has emerged from neuroendocrinological research and rodent models, while hair experts have performed investigations into the plausibility of the syndrome based on a comprehensive review of the respective medical literature, and found that persistent sexual side effects were only documented in low-quality studies with strong bias selection, and a significant nocebo effect. In fact, there is more evidence that the condition may represent a psychiatric disorder. In favor of this hypothesis are a striking similarity to Koro with regard to genital symptoms; emergence of the condition with media coverage; a known significant nocebo effect in patients informed about adverse effects of finasteride; high prevalence of personality disorders among men seeking treatment for MPHL; so far no consistent endocrinological or organic abnormalities; and quality of centrality: No matter how unlikely it is that these strange things are happening, the patient accepts them relatively unquestioningly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.